- Hualu Hengsheng reported a net income of 706.9 million yuan for the first quarter of 2025.
- The company’s total revenue for the same period was 7.77 billion yuan.
- Analyst ratings show strong confidence in Hualu Hengsheng, with 26 analysts recommending a buy.
- There are no hold or sell recommendations for Hualu Hengsheng at this time.
“`
A look at Shandong Hualu Hengsheng A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shandong Hualu Hengsheng Chemical Co., Ltd., a company known for manufacturing a variety of chemical products including urea, methanol, and formaldehyde, has recently been assessed using Smartkarma Smart Scores. The scores highlight different aspects of the company’s performance. With a high score of 5 in dividends, Shandong Hualu Hengsheng A shows a strong commitment to rewarding its investors. Additionally, scoring well in value and resilience with scores of 4, the company demonstrates good financial health and stability. However, its growth and momentum scores are slightly lower at 3, indicating moderate potential for future expansion and stock price movement.
In light of the Smartkarma Smart Scores assessment, the long-term outlook for Shandong Hualu Hengsheng A appears promising. The high dividend score signifies consistent returns for investors, while the strong performance in value and resilience points towards a reliable and financially sound company. Although there is room for improvement in growth and momentum, the overall scores suggest that Shandong Hualu Hengsheng A is well-positioned for steady growth and resilience in the market, making it a potentially attractive investment for those seeking stable returns in the chemical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
